Horizon Pharmaceuticals $510 million acquisition of Crealta Pharmaceuticals

13/1/2016

Private acquisition

Value:

$ 510 million

Status:

Completed

Date:

13/1/2016

Overview:

Horizon Pharmaceuticals has acquired Crealta Pharmaceuticals in a transaction worth $510 million.
Crealta Pharmaceuticals is a portfolio company of GTCR, a Chicago-based private equity firm.

Rani Mehta - Journalist

Jurisdiction:

United States

Deal type:

Private acquisition

Practice area:

M&A

Industry sector:

Pharmaceuticals and life sciences

Firm:

Kirkland & Ellis

Party: Crealta Pharmaceuticals (Target)

Lawyer: Sanford Perl

Related deals